**Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation.** Joanie Vaillancourt, Véronique Turcotte, Patrick Caron, Lyne Villeneuve, Louis Lacombe, Frédéric Pouliot, Éric Lévesque, and Chantal Guillemette .............................. 75

**Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate.** Aaron G. Bart, Ryan H. Takahashi, Xiaojing Wang, and Emily E. Scott ................................................................. 86


**N-Oxygenation of Oxycodone and Retro-reduction of Oxycodone N-Oxide.** John R. Cashman, Mark Gohdes, Annelies de Kater, and Grant Schoenhard .......................... 106


**Piperine Is a Mechanism-Based Inactivator of CYP3A.** Tiantian Cui, Qian Wang, Xiaoxiao Tian, Kehan Zhang, Ying Peng, and Jiang Zheng ............................ 123

**Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes.** Yasuo Uchida, Ryohei Goto, Hina Takeuchi, Magdalena Łuczak, Takuya Usui, Masanori Tachikawa, and Tetsuya Terasaki ................ 135

**ERRATUM**

Correction to “Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19” ................................. 85

[Supplemental material is available online at http://dmd.aspetjournals.org.]

About the cover: The antiandrogen abiraterone and its metabolites are glucuronidated by UGT1A4 and inhibit steroid glucuronidation. See the article by Vaillancourt et al. (dx.doi.org/10.1124/dmd.119.088229).